Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T12:05:43.348Z.
Calculation as of: 2026-10-06T12:05:43.348Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e8745362276acfcd64f5b9abcba69827836693d7b304a16c872192b0535814a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12B
Free Cash Flow Yield
N/A
TTM Avg
3.10%
3Y Avg
4.04%
5Y Avg
3.98%
Market Cap
$1.12B
Free Cash Flow Yield
13.67%
TTM Avg
12.18%
3Y Avg
9.49%
5Y Avg
7.36%
Market Cap
$1.16B
Free Cash Flow Yield
12.51%
TTM Avg
11.24%
3Y Avg
6.85%
5Y Avg
5.53%
Market Cap
$1.20B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.21B
Free Cash Flow Yield
4.09%
TTM Avg
2.05%
3Y Avg
1.76%
5Y Avg
1.76%
Market Cap
$1.05B
Free Cash Flow Yield
21.36%
TTM Avg
18.91%
3Y Avg
16.36%
5Y Avg
12.15%
Market Cap
$1.24B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$989.05M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | N/A | 3.10% | 4.04% | 3.98% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 13.67% | 12.18% | 9.49% | 7.36% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 12.51% | 11.24% | 6.85% | 5.53% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.21B | 4.09% | 2.05% | 1.76% | 1.76% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 21.36% | 18.91% | 16.36% | 12.15% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
